Allspring Global Investments
VKTX icon

Allspring Global Investments’s Viking Therapeutics VKTX Stock Holding History

Allspring Global Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-605
Closed -$38.3K – 2411
2024
Q3 		$38.3K Sell
605
-3,065
-84% -$180K ﹤0.01% 1889
2024
Q2 		$195K Sell
3,670
-54,566
-94% -$3.58M ﹤0.01% 1712
2024
Q1 		$4.78M Buy
+58,236
New +$2.59M 0.01% 969
2023
Q4 		– Sell
-11,048
Closed -$122K – 2759
2023
Q3 		$122K Buy
11,048
+8,063
+270% +$115K ﹤0.01% 1931
2023
Q2 		$48.4K Buy
+2,985
New +$62.5K ﹤0.01% 2297
2022
Q2 		– Sell
-46,677
Closed -$140K – 2949
2022
Q1 		$140K Buy
46,677
+3,823
+9% +$13.7K ﹤0.01% 2679
2021
Q4 		$197K Buy
+42,854
New +$240K ﹤0.01% 2638

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments's VKTX Position: Q4 2024 in Review

Allspring Global Investments sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 605 shares — an estimated $38.3K sold.

Allspring Global Investments first reported a position in VKTX in Q4 2021 and held it in 7 quarters. The position peaked at $4.78M in Q1 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Allspring Global Investments reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 605 Viking Therapeutics shares in Q4 2024, an estimated $38.3K.
  • Allspring Global Investments first reported a position in Viking Therapeutics in Q4 2021 and held it in 7 quarters.
  • Allspring Global Investments's Viking Therapeutics position peaked at $4.78M in Q1 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.